News and Press Release

October 30, 2020  LATITUDE Pharmaceuticals Receives Grant to Develop a Small-Volume Injectable Formulation for Remdesivir

May 06, 2020         LATITUDE Pharmaceuticals Develops an SC/IM Injectable Remdesivir Formulation

May 08, 2019          LATITUDE Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Stabile Aqueous Vancomycin Formulations

Jan 17, 2019           LATITUDE Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Stabilized Aqueous Glucagon Formulations

Sep 20, 2016          LATITUDE Pharmaceuticals Receives USPTO Notice of Allowance for Novel Injectable Depot Formulation Platform

Mar 03, 2016          LATITUDE Pharmaceuticals’ Nano-E and PG Depot Featured in March 2016 Issue of Drug Development & Delivery

Jan 11, 2016          LATITUDE Announces New Chinese Patent Granted to Nanoemulsion Composition Containing Vitamin K

Dec 01, 2015          LATITUDE Hires Senior Director of Business Development

Nov 09, 2015          LATITUDE Announces Recent Chinese Patent granted to PG Depot

Sep 20, 2015          Cidara Therapeutics Presents Poster on Novel Echinocandin CD101 Gel Formulation by LATITUDE at ICAAC/ICC 2015

Jun 20, 2013          JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon

Mar 18, 2013          Helmsley Press Release T1D funding

Apr 03, 2012          LATITUDE Pharmaceuticals, Inc. Develops a Stable Liquid Glucagon Formulation

Apr 14, 2010          LATITUDE Pharmaceuticals Initiates Four Additional Collaboration Studies For Its PG Depot 

Sep 15, 2009          Nano-E Antibacterial Emulsion Poster 49th ICAAC Annual Meeting

Jul  16, 2009          LATITUDE Signs Two More Collaboration Studies for PG Depot

May 12, 2009         Nanoemulsions are a Superior Approach to Formulating Insoluble IV Drugs

May 07, 2009         ADVENTRX Announces Results form ANX-514 Bioequivalence Trial

May 16, 2008         ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

May 10, 2008         Novalar Receives FDA Approval For OraVerse